Research funder · United States
Alzheimer's Drug Discovery Foundation
Nonprofit organization
- Grants since 2016
- 326
- Awarded, last 5 years (where amounts are published)
- $245.1M
- Funded works, last 5 years
- 1 178
- Funded works, all time
- 2 272
Grants
2018–2021 · research · Prevention
Minimizing blood pressure variability with antihypertensive drugs to reduce dementia risk: an IPD meta-analysis of cohort studies in the CAPA consortium
Phillip Tully · The University of Adelaide
2018–2019 · research · Drug Discovery
Evaluation and development of optimized PDI modulators for AD
Brent Stockwell · Trustees Of Columbia University In The City Of New York
2018–2021 · research · Drug Discovery
Rescue of lysosomal dysfunction, neuroinflammation, and neurodegeneration by lysosomal GRN-2 in a mouse model of PGRN deficiency and Frontotemporal Dementia
Thomas Kukar · Emory University
2018–2019 · research · Drug Discovery
Optimization of Novel Positive Allosteric Modulators of the Alpha1A-Adrenergic Receptor to treat Alzheimer's Disease
Dianne Perez · Cleveland Clinic
2018–2023 · research · Clinical
Evaluating the effects of the novel GLP-I analogue, liraglutide, in patients with Alzheimer's disease (ELAD Study) - Open Label Extension
Paul Edison · Imperial College London
2018–2020 · research · Clinical
De-risking the therapeutic opportunity of HDAC6 for neurodegenerative tauopathies
Janice Kranz · Eikonizo Therapeutics, Inc.
2018–2019 · research · Drug Discovery
Novel human FTLD neuron and microglia cell models for drug discovery
Steven Finkbeiner · Gladstone Institutes
2018–2023 · research · Biomarkers
Alzheimer's Disease Neuroimaging Initiative (ADNI) 3
Joe Menetski · Foundation For The National Institutes Of Health, Inc.
2018–2020 · research · Biomarkers
Inflammatory Markers for Early Detection & Subtyping of Neurodegenerative & Mood Disorders
Rohini Khilian · Foundation For The National Institutes Of Health, Inc.
2018–2020 · research · Prevention
Connection Between Depressive Symptoms and Dementia: When Best to Intervene.
Kristine Yaffe · University of California, San Francisco
2018–2020 · research · Drug Discovery
Small Molecule Inhibitors of Mitochondrial Complex I for Treatment of Alzheimer's Disease
Eugenia Trushina · Mayo Clinic
2018–2023 · research · Clinical
Phase I study of an AAVrh.10-mediated Apolipoprotein E2 Gene Delivery to the CNS for the treatment of Alzheimer's Disease in E4 Homozygotes .
Ronald Crystal · Cornell University
2017–2020 · research · Drug Discovery
Targeting Ca2+ dysregulation in Alzheimer's Disease
Thomas Franke · Icahn School of Medicine at Mount Sinai
2017–2018 · research · Drug Discovery
Ryanodine receptor inhibitors as a treatment for AD
Grace Stutzmann · Neurolucent, Inc
2017–2020 · research · Clinical
Manufacturing of Allopregnanolone for Phase 2 Clinical Trial
Roberta Diaz Brinton · University of Arizona
2017–2018 · research · Drug Discovery
Preclinical assessment of the therapeutic utility of small molecule inhibitors of the calcineurin/NFAT system in Alzheimer's disease
Christopher Norris · University Of Kentucky (p)
2017–2021 · research · Prevention
Exploring the Role of Inflammation in Long-Term Cognitive Decline Following Surgery and Delirium
Sharon Inouye · Hebrew SeniorLife
2017–2019 · research · Drug Discovery
IND-enabling program and Phase 1 clinical trial for Yuma Therapeutics' novel and proprietary lead Hsp90 inhibitor, YT-83, for the treatment of Alzheimer's disease
Yukari Perrella · Yuma Therapeutics Corporation
2017–2018 · research · Drug Discovery
Development of small molecule activators of glutamate transporter EAAT2 translation for AD (Year Three- bridge funding)
Chien-Liang Lin · The Ohio State University
2017–2018 · research · Drug Discovery
A novel neuroprotective compound targeting endogenous function of C9ORF72 in vivo
Justin Ichida · University of Southern California
2017–2018 · research · Clinical
Accelerating Manufacture of Clinical Supplies for Initiation of Patient Enrollment in the HOPE4MCI Phase 3 Trial (AgeneBio, AGB101)
Sharon Rosenzweig-Lipson · AgeneBio (United States)
2017–2018 · research · Drug Discovery
Selective Cyclophilin D inhibitors for neurodegeneration
Michael Peel · Cypralis Ltd
2017–2018 · research · Drug Discovery
GABA-A alpha-5 Positive Allosteric Modulators for the treatment of aMCI due to AD.
Sharon Rosenzweig-Lipson · AgeneBio (United States)
2017–2019 · research · Drug Discovery
Targeting APOE e4 in Alzheimer's Disease by novel RNA-based therapeutic compounds
Evgeny Rogaev · University of Massachusetts Boston
2017–2028 · research · Clinical
A phase 2 repurposing trial of senicapoc for prodromal and mild Alzheimer’s disease
John Olichney · University of California, Davis
2017–2018 · research · Biomarkers
Plasma Abeta protein complexes for the early detection of brain amyloid accumulation.
Blaine Roberts · Florey Institute of Neuroscience and Mental Health
2017–2018 · research · Drug Discovery
Target identification and mode of action studies for novel NLRP3 inflammasome inhibitors
Shijun Zhang · Virginia Commonwealth University
2017–2018 · research · Drug Discovery
Parthanatos Inhibitors for Neuroprotection
Valina Dawson · Johns Hopkins University
2017–2020 · research · Clinical
Non-invasive brain stimulation to restore cortical plasticity and connectivity in genetic and sporadic FTD
Barbara Borroni · University of Brescia
2017–2018 · research · Clinical
A Pilot Project to Enhance Recruitment into Clinical Trials Supported by ADDF
Richard Mohs · Global Alzheimer's Platform Foundation
2017–2018 · research · Drug Discovery
Mitochondrial TDP-43 as a Novel Therapeutic Target for FTD
Xinglong Wang · Case Western Reserve University
2017–2018 · research · Biomarkers
Clinical development of a companion marker for treatment with the dual LSD1/MAO-B inhibitor ORY-2001
Tamara Maes · Oryzon Genomics S.a.
2017–2018 · research · Drug Discovery
Exploratory Optimization of New CX3CR1 modulators for the treatment of AD.
Paolo Pevarello · Axxam (Italy)
2017–2018 · prize · Drug Discovery
2016 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery: Catalyzing p38aMAPKI Drug Candidate, MW150, Into the Clinic
D. Watterson · Neurokine Therapeutics
2017 · research · Drug Discovery
Targeting Ca2+ dysregulation in Alzheimer's Disease
Thomas Franke · New York University
2017–2020 · research · Biomarkers
A blood test to predict Alzheimer's based on fluorescence spectroscopy
Peter Stys · University of Calgary
2017–2018 · research · Drug Discovery
Testing of selective DYRK1A inhibitors as a novel treatment for AD - ADD ON
Travis Dunckley · Asu Foundation For A New American University
2017–2022 · research · Clinical
Prevention of cognitive decline in older adults with low DHA/EPA index in red blood cells (Acronym : MAPT 2)
Bruno Vellas · Toulouse Centre Of Excellence In Neurodegeneration, University Hospital Toulouse
2017–2025 · prize · Clinical
2017 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery: Allopregnanolone Novel Patentable Formulation to Advance Commercialization
Roberta Diaz Brinton · University of Arizona
2017–2021 · research · Drug Discovery
Fragment-Based Inhibitor Design of human Scps for Neuron Regeneration
Yan Zhang · The University of Texas at Austin